ENTA’s cash balance at 9/30/14 was $131.8M, a slight decrease from the $137.6M at 6/30/14. Adding in the expected $150M in milestone payments from ABBV for FDA and EMA approval of the 3-DAA HCV regimen (#msg-100940717), absent a glitch ENTA’s cash should balloon to roughly $280M in the next couple of months, without even counting royalties on sales of ABBV’s 3-DAA regimen.
Market Data 
Markets 
AI
